Bicalutamide and Goserelin or Leuprolide Acetate With or Without Cixutumumab in Treating Patients With Newly Diagnosed Metastatic Prostate Cancer

NCT01120236 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

211

Enrollment

NIH

Sponsor class

Conditions

Prostate Adenocarcinoma
Recurrent Prostate Carcinoma
Stage IV Prostate Cancer

Interventions

DRUG: Bicalutamide
BIOLOGICAL: Cixutumumab
DRUG: Goserelin Acetate
OTHER: Laboratory Biomarker Analysis
DRUG: Leuprolide Acetate
OTHER: Pharmacological Study

Sponsor

National Cancer Institute (NCI)